ライフサイエンスコーパス: fallypride

1 of the dopamine D(2)/D(3) antagonist [(18)F]fallypride.

2 scan with the high affinity D2R tracer [18 F]fallypride.

3 nalysis and by radioligand assay using (18)F-fallypride.

4 hMSC-D2R80A showed specific binding of (18)F-fallypride.

5 thymic rats was performed by PET using (18)F-fallypride.

6 cated by binding potential (BPND) for [(18)F]fallypride.

7 ET scanning with the D(2)/D(3) ligand [(18)F]fallypride.

8 dopamine D-2/D-3 receptor radioligand, (18)F-fallypride.

9 After intravenous (18)F-fallypride (28-37 MBq) administration, normal rats and r

10 atched HC (21 M; 10 F) subjects using [(18)F]fallypride, a high-affinity D(2/3) receptor ligand, to m

11 All completed PET imaging with 18F-fallypride, a high-affinity D2-like receptor ligand, in

12 (18)F-fallypride and (18)F-fluoromisonidazole were successfull

13 (18)F-fallypride and (18)F-fluoromisonidazole, two well-establ

14 D(2)/D(3) dopamine receptor ligand [(1)(8)F]fallypride and BOLD fMRI while they performed the Stop-s

15 the spleen were visualized in vivo by (18)F-fallypride and confirmed by immunostaining.

16 a dual-scan PET imaging protocol with [(18)F]fallypride and d-amphetamine to measure DA responsivity

17 receptor availability, measured with [(18)F]fallypride and positron emission tomography (PET).

18 als ([(18)F]Flumazenil, [(18)F]PBR06, [(18)F]Fallypride, and [(18)F]FEPPA), performing > 800 experime

19 alities, including (11)C, (15)O-water, (18)F-fallypride, and L-3,4-dihydroxy-6-(18)F-fluorophenylalan

20 s demonstrate the potential utility of (18)F-fallypride as a PET agent for islet cells.

21 tron emission tomography imaging with [(18)F]fallypride at baseline and after administration of oral

22 sitron emission tomography (PET) with [(18)F]fallypride before and after an oral dose of d-amphetamin

23 of islets by streptozotocin decreased (18)F-fallypride binding in pancreas by greater than 50%, para

24 The decrease in (18)F-fallypride binding in the extrastriatal regions points t

25 (18)F-fallypride binding to isolated rat islets and pancreas w

26 (18)F-fallypride bound to isolated islet cells and pancreatic

27 20, 65-79 years); (ii) pharmacokinetic, 18F-fallypride D2/3 receptor imaging and clinical outcome da

28 een behavioral switch costs and vmPFC [(18)F]fallypride displacement suggested that participants show

29 accounts for time-dependent changes in (18)F-fallypride displacement.

30 le, we synthesized several transport peptide-fallypride fusion molecules as model systems and determi

31 ans, 19 post-treatment scans); and (iii) 18F-fallypride imaging of an antipsychotic free Alzheimer's

32 ing positron emission tomography with [(18)F]fallypride in 43 human subjects with body mass indices (

33 12 MBq of the D(2/3) receptor ligand [(18)F]fallypride in a block design with 2 parts.

34 OPA and dopamine D2/3 receptor ligand [(18)F]fallypride in aged transgenic rats carrying human pathog

35 l decrease in the binding potential of (18)F-fallypride in extrastriatal regions: thalamus (-20%), am

36 Uptake of (18)F-fallypride in the pancreas was confirmed by radiochromat

37 odel was used to study localization of (18)F-fallypride in the pancreas, in vitro and ex vivo.

38 -amphetamine-induced displacements of [(18)F]fallypride in the striatal and extrastriatal brain regio

39 acement of the D(2/3) receptor ligand [(18)F]fallypride in the vmPFC (maximum T value = 13.8; cluster

40 orter for in vivo hMPC PET tracking by (18)F-fallypride is a significant step toward potential noninv

41 r and subsequently studied ex vivo for (18)F-fallypride localization in the pancreas.

42 found a negative correlation between [(18)F]fallypride nondisplaceable binding potential (BP(ND)) an

43 e high-affinity D(2/3) PET radioligand (18)F-fallypride offers the possibility of measuring both stri

44 connectivity (FC) using simultaneous [(18)F]fallypride PET and resting-state fMRI in awake male rhes

45 ility in an overlapping cohort using [(18)F]-fallypride PET did not identify any effects of genetic r

46 this genotype.These results show that [(18)F]fallypride PET imaging is sensitive to dysregulation of

47 ponsiveness that can be measured using (18)F-fallypride PET in a single scanning session.

48 ng of task administration for a single (18)F-fallypride PET protocol and the linearized simplified re

49 hy volunteers underwent a single-bolus (18)F-fallypride PET protocol.

50 or impulsivity and underwent a second [(18)F]fallypride PET scan.

51 or impulsivity and underwent a second [(18)F]fallypride PET scan.

52 Here, we applied 18F-fallypride PET studies to assess striatal and extrastria

53 e of trait impulsivity and concurrent [(18)F]fallypride PET, a method that allows quantification of D

54 d into the spleen and visualized using (18)F-fallypride PET.

55 Using [(18)F]fallypride positron emission tomography and blood oxygen

56 Through the combined use of (18)F-fallypride positron emission tomography and magnetic res

57 26 healthy control subjects underwent [(18)F]fallypride positron emission tomography to measure ventr

58 e used magnetic resonance imaging and [(18)F]fallypride positron emission tomography, respectively, t

59 Participants completed [(18)F]fallypride positron emission topography (PET) imaging in

60 ded d-amphetamine (dAMPH) study, with [(18)F]fallypride positron emission topography (PET) imaging, a

61 aseline PET scan with the D2/3 ligand [(18)F]fallypride, rats received 6 mg/kg MPH, orally, twice eac

62 aseline PET scan with the D2/3 ligand [(18)F]fallypride, rats were trained to self-administer cocaine

63 on tomography with [(11)C]NNC-112 and [(18)F]fallypride, respectively.

64 When a single (18)F-fallypride scanning protocol is used, task timing is cri

65 rats demonstrated greater binding of [(18)F]fallypride than LRRK2-G2019S or non-transgenic controls,

66 itron emission tomography (PET) using [(18)F]fallypride to determine the effects of the 8-week interv

67 Specific binding of (18)F-fallypride to hD2R hMPCs was demonstrated in vitro and i

68 ron emission tomography was used with [(18)F]fallypride to measure BPND in a midbrain region, encompa

69 rmore, our findings support the use of (18)F-fallypride to measure extrastriatal dopamine release.

70 and positron emission tomography with [(18)F]fallypride to measure striatal dopamine D(2)/D(3) recept

71 The ratio of (18)F-fallypride uptake in the pancreas to reference tissue (e

72 [(18)F]fallypride was used to measure D2/D3 baseline receptor a

73 s with amphetamine and the D2/D3 ligand [18F]fallypride, we found that higher levels of trait impulsi

74 PET scans with [(18)F]fallypride were performed on these 2 days, and serum 17B